Baysient’s T3 Provides Therapeutic Drug Monitoring for Subcutaneous Infliximab and Adalimumab
Baysient announces updates to its therapeutic drug monitoring app Time To Target (T3) to enable clinicians to deliver personalized dosing recommendations for the subcutaneous forms of Infliximab and adalimumab. Inflammatory bowel disease (IBD) is a chronic condition affecting approximately 3…